Matrix Metalloproteinase-1 and Tissue Inhibitor of Metalloproteinases-1 Levels in Severely Obese Patients: What is the Effect of Weight Loss?

Abstract

Introduction: There is increased evidence that circulating levels of matrix metalloproteinases and their tissue inhibitors are altered in obesity and may be implicated in its pathogenesis. This study aimed to compare the serum concentrations of pro-matrix metalloproteinase-1 (pro-MMP-1) and tissue inhibitor of metalloproteinases-1 (TIMP-1) in severely obese patients with or without metabolic syndrome, and to investigate the potential effect of weight loss on their circulating levels.

Methods: A total of 102 severely obese subjects were included in our study. Of these, 61 had no other features of metabolic syndrome, while the rest were 41 age- and sex-matched subjects with severe obesity and metabolic syndrome according to the NCEP-ATP criteria. Fourty-two age and sex-matched healthy lean individuals were used as controls.

Results: Severely obese subjects had higher circulating levels of TIMP-1 than the lean ones (120.6±50.6 vs. 89.0±35.2 ng/ml) and obese patients with metabolic syndrome had higher TIMP-1 levels than their metabolically healthy counterparts (134.8±38.4 vs. 111.0±55.62 ng/ml). A positive association was also found between TIMP-1 levels and various anthropometric and metabolic parameters in the obese subjects. Moreover, weight loss of more than 5% resulted in a significant reduction of the TIMP-1 levels in obese subjects, irrespective of the presence or not of metabolic syndrome. No significant differences in pro-MMP-1 concentrations were found between the obese (2.8±2.4 ng/ml) and lean individuals (2.8±0.8 ng/ml).

Conclusions: In conclusion, we demonstrated that increased TIMP-1 serum levels are found in severely obese patients and particularly in these with metabolic syndrome, while weight loss of more than 5% resulted in reduction of TIMP-1 levels.

Key words

obesity - metabolic syndrome - metalloproteinases - weight loss

References

• 1 Beaudeux JL, Giral P, Bruckert E. et al . Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives.  Clin Chem Lab Med. 2004;  42 121-131
• 2 Belo VA, Souza-Costa DC, Lana CM. et al . Assessment of matrix metalloproteinase (MMP)-2, MMP-8, MMP-9, and their inhibitors, the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in obese children and adolescents.  Clin Biochem. 2009;  42 984-990
• 3 Boden G, Song W, Kresge K. et al . Effects of hyperinsulinemia on hepatic metalloproteinases and their tissue inhibitors.  Am J Physiol Endocrinol Metab. 2008;  295 E692-E697
• 4 Chavey C, Mari B, Monthouel MN. et al . Matrix metalloproteinases are differentially expressed in adipose tissue during obesity and modulate adipocyte differentiation.  J Biol Chem. 2003;  278 11888-11896
• 5 Chobanian AV, Bakris GL, Black HR. et al . The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.  Hypertension. 2003;  42 1206-1252
• 6 Crandall DL, Hausman GJ, Kral JG. A review of the microcirculation of adipose tissue: anatomic, metabolic, and angiogenic perspectives.  Microcirculation. 1997;  4 211-232
• 7 Demeulemeester D, Scroyen I, Voros G. et al . Overexpression of tissue inhibitor of matrix metalloproteinases-1 (TIMP-1) in mice does not affect adipogenesis or adipose tissue development.  Thromb Haemost. 2006;  95 1019-1024
• 8 Deulemeester D, Collen D, Lijnen HR. Effect of matrix metalloproteinase inhibition on adipose tissue development.  Biochem Biophys Res Commun. 2005;  329 105-110
• 9 Gerin I, Louis GW, Zhang X. et al . Hyperphagia and obesity in female mice lacking tissue inhibitor of metalloproteinase-1.  Endocrinology. 2009;  150 1697-1704
• 10 Glowinska-Olszewska B, Urban M. Elevated matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 in obese children and adolescents.  Metabolism. 2007;  56 799-805
• 11 González-Reimers E, Castellano-Higuera A, Alemán-Valls R. et al . Relation between Body Fat and Liver Fat Accumulation and Cytokine Pattern in Non-Alcoholic Patients with Chronic HCV Infection.  Ann Nutr Metab. 2009;  55 351-357
• 12 Grundy SM, Cleeman JI, Daniels SR. et al . American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive Summary.  Circulation. 2005;  112 e285-e290
• 13 Harris AK, Hutchinson JR, Sachidanandam K. et al . Type 2 diabetes causes remodeling of cerebrovasculature via differential regulation of matrix metalloproteinases and collagen synthesis: role of endothelin-1.  Diabetes. 2005;  54 2638-2644
• 14 Hayakawa T, Yamashita K, Tanzawa K. et al . Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum.  FEBS Lett. 1992;  298 29-32
• 15 Kosmala W, Plaksej R, Przewlocka-Kosmala M. et al . Matrix metalloproteinases 2 and 9 and their tissue inhibitors 1 and 2 in premenopausal obese women: relationship to cardiac function.  Int J Obes (Lond). 2008;  32 763-771
• 16 Kralisch S, Bluher M, Tonjes A. et al . Tissue inhibitor of metalloproteinase-1 predicts adiposity in humans.  Eur J Endocrinol. 2007;  156 257-261
• 17 Kralisch S, Klein J, Lossner U. et al . Proinflammatory adipocytokines induce TIMP-1 expression in 3T3-L1 adipocytes.  FEBS Lett. 2005;  579 6417-6422
• 18 Laimer M, Kaser S, Kranebitter M. et al . Effect of pronounced weight loss on the nontraditional cardiovascular risk marker matrix metalloproteinase-9 in middle-aged morbidly obese women.  Int J Obes (Lond). 2005;  29 498-501
• 19 Lijnen HR, Demeulemeester D, Van Hoef B. et al . Deficiency of tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) impairs nutritionally induced obesity in mice.  Thrombosis and Haemostasis. 2003;  89 249-255
• 20 Lijnen HR, Maquoi E, Hansen LB. et al . Matrix metalloproteinase inhibition impairs adipose tissue development in mice.  Arterioscler Thromb Vasc Biol. 2002;  22 374-379
• 21 Madsen EL, Bruun JM, Skogstrand K. et al . Long-term weight loss decreases the nontraditional cardiovascular risk factors interleukin-18 and matrix metalloproteinase-9 in obese subjects.  Metabolism. 2009;  58 946-953
• 22 Maquoi E, Munaut C, Colige A. et al . Modulation of adipose tissue expression of murine matrix metalloproteinases and their tissue inhibitors with obesity.  Diabetes. 2002;  51 1093-1101
• 23 Maury E, Ehala-Aleksejev K, Guiot Y. et al . Adipokines oversecreted by omental adipose tissue in human obesity.  Am J Physiol Endocrinol Metab. 2007;  293 E656-E665
• 24 Mu H, Ohashi R, Yan S. et al . Adipokine resistin promotes in vitro angiogenesis of human endothelial cells.  Cardiovasc Res. 2006;  70 146-157
• 25 Nho YK, Ha E, Yu KI. et al . Matrix metalloproteinase-1 promoter is associated with body mass index in Korean population with aged greater or equal to 50 years.  Clin Chim Acta. 2008;  396 14-17
• 26 O’Hara A, Lim FL, Mazzatti DJ. et al . Microarray analysis identifies matrix metalloproteinases (MMPs) as key genes whose expression is up-regulated in human adipocytes by macrophage-conditioned medium.  Pflugers Arch. 2009;  458 1103-1114
• 27 Page-McCaw A, Ewald AJ, Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling.  Nature Rev Mol Cell Biol. 2007;  8 221-233
• 28 Pendás AM, Folgueras AR, Llano E. et al . Diet-induced obesity and reduced skin cancer susceptibility in matrix metalloproteinase 19-deficient mice.  Mol Cell Biol. 2004;  24 5304-5313
• 29 Pi-Sunyer FX. The obesity epidemic: pathophysiology and consequences of obesity.  Obes Res. 2002;  10 (S 02) S97-S104
• 30 Portik-Dobos V, Anstadt MP, Hutchinson J. et al . Evidence for a matrix metalloproteinase induction/activation system in arterial vasculature and decreased synthesis and activity in diabetes.  Diabetes. 2002;  51 3063-3068
• 31 Scroyen I, Cosemans L, Lijnen HR. Effect of tissue inhibitor of matrix metalloproteinases-1 on in vitro and in vivo adipocyte differentiation.  Thromb Res. 2009;  124 578-583
• 32 Vu TH, Werb Z. Matrix metalloproteinases: effectors of development and normal physiology.  Genes Dev. 2000;  14 2123-2133

Correspondence